BenevolentAI SPAC Presentation Deck

4 Molecular Design - Expertise in structure-based design, virtual screening and machine learning We combine deep expertise in drug discovery with innovative techniques in structure-based design, virtual screening and machine learning. Highly experienced drug discovery team with a proven track record of taking nascent programme ideas and delivering drugs to the clinic Chemoinformatic and Al tools impacting all stages of a drug programme from target selection through to candidate nomination Empowering chemists to design better drugs in fewer cycles - candidate drugs delivered in as little as 2 years from programme inception compared to 3-5 year industry standard Druggability scoring to prioritise targets Target ID Binding site comparison to identify Hit matter and evaluate selectivity Hit Identification Binding site detection to identify differentiating chemistry opportunities Hit Expansion Customisable virtual screening pipeline now on >10 billion compound scale Proprietary pharmacophore building methodology Lead Optimisation ML models of activity and ADMET endpoints Candidate Seeking Protein-Ligand interaction mining to surface protein-centric bioisosteres Programme visualisation Benevolent 17

View entire presentation